[Nuclear factor kappa B in the treatment of inflammatory and tumor diseases].
Since its discovery in 1986 nuclear factor kappa B attracted attention of scientists all over the world. Intensive research has proved its indisputable role in pathogenesis of particularly inflammatory and tumor diseases and revealed many possibilities in the modulation of its function. For some of the modulators distinct therapeutic effects have been proved in in vitro and in vivo studies or even in the clinical trials, some of them are still to be tested. One may expect wide use of different inhibitors or modulators of nuclear factor kappa B in various indications, which will markedly enhance the therapeutic effect.
Lenícek
M
M
Ustav klinické biochemie a laboratorní diagnostiky 1. LF UK a VFN, Praha. mleni@centrum.cz
Muchová
L
L
Vítek
L
L
D017209:Apoptosis / Q000502:physiology; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000503:physiopathology; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000502:physiology*; D009369:Neoplasms / Q000188:drug therapy* / Q000503:physiopathology
D016328:NF-kappa B